Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes;一名接受达格列净治疗的2型糖尿病患者发生的Fournier's坏疽

Journal of Diabetes

Volumn 11, Issue 5, 2019, Pages 348-350

  Onder, Cagatay E ^a   Gursoy, Koray ^a   Kuskonmaz, Serife M ^a   Kocer, Ugur ^a   Culha, Cavit ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

dapagliflozin; fournier's gangrene; SGLT2 inhibitors

Indexed keywords

CEFTRIAXONE; DAPAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; METRONIDAZOLE; VILDAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ARTICLE; BODY MASS; BODY TEMPERATURE; CASE REPORT; CLINICAL ARTICLE; COLOSTOMY; DOPPLER ULTRASONOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY WARD; EX-SMOKER; FASCIOCUTANEOUS FLAP; FOURNIER GANGRENE; HEMORRHOID; HUMAN; INGUINAL LYMPH NODE; LYMPHADENOPATHY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCROTAL PAIN; SCROTAL SWELLING; CHEMICALLY INDUCED; PATHOLOGY; PROGNOSIS;

BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; FOURNIER GANGRENE; GLUCOSIDES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85061007971     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12896     Document Type: Article

References (11)

1. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297-322.
2. Cefalu WT, Riddle MC. SLGT2 inhibitors: the latest new kids on the block. Diabetes Care. 2015;38:352-354.
3. Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg. 2000;87:718-728.
4. Ruiz-Tovar J, Córdoba L, Devesa JM. Prognostic factors in Fournier gangrene. Asian J Surg. 2012;35:37-41.
5. Sorensen MD, Krieger JN. Fournier's gangrene: epidemiology and outcomes in the general US population. Urol Int. 2016;97:249-259.
6. Stevens DL, Bryant AE. Necrotizing soft-tissue infections. N EnglJ Med. 2017;377:2253-2265.
7. Bonne SL, Kadri SS. Evaluation and management of necrotizing soft tissue infections. Infect Dis Clin North Am. 2017;31:497-511.
8. Wong CH, Khin LW, Heng KS, et al. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32:1535-1541.
9. Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT2 inhibitors and the risk of infections: a systematic review and meta analysis of randomized controlled trials. Acta Diabetol. 2018;55:503-514.
10. Chi WC, Lim-Tio S. Fournier's syndrome: a life threatening complication of SGLT-2 inhibition in poorly controlled diabetes mellitus. Paper presented at: ADS ADEA Annual Scientific Meeting, August 24-26, 2016, Queensland.
11. Kumar S, Costello AJ, Colman PG. Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes. Diabet Med. 2017;34:1646-1648.